PERCEPTIVE INFORMATICS SURVEY RESULTS REVEAL BIOPHARMACEUTICAL INDUSTRY'S VIEW ON MOST IMPORTANT eCLINICAL ATTRIBUTES
Boston, MA, March 24, 2011 — Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of a survey conducted during its recent webinar entitled “Designing and Delivering an eClinical Product Suite.” Perceptive polled biopharmaceutical industry professionals across a broad range of clinical, data management and IT functions about their views on the important attributes of an eClinical suite, and the associated value to sites and sponsors.
Survey results revealed that over half (53%) of respondents view integration to be the most important attribute of an eClinical suite. These respondents indicate that the data exchange between applications to prevent duplication of activities and the need for database reconciliation is critical. Another 29% believe that the functionality of an eClinical suite should simplify workflow for various users. A smaller group of respondents (18%) feel that a key attribute of an eClinical suite is the ability to receive consolidated data. These respondents believe that having a single view of performance across multiple applications is important to improving processes and the accuracy of clinical trial data.
According to Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics, “I believe that the biopharmaceutical industry is increasingly recognizing that an eClinical suite can help to improve data quality, streamline workflow and enhance user experience. At Perceptive, we are focused on providing even greater value through our eClinical Suite with regard to ease of use, visibility to data, elimination of redundant data entry and the reduced need for the reconciliation of various databases. We are applying the concept of convergence to our eClinical Suite, which goes beyond what the term “integration” implies. Integration typically requires an additional technical solution to facilitate communication between systems, whereas convergence involves truly interoperable systems that have a greater level of connectedness to facilitate real-time data interchange.”
During the webinar, Dr. Byrom and Andy Harrod, Senior Director, Enterprise Architecture at Perceptive Informatics, presented case study examples and approaches for implementing an eClinical suite to enable the most efficient workflow by simplifying the use of multiple technologies and optimizing them for the way users manage clinical trials. The experts discussed how eClinical solutions can be delivered in a scalable manner, as well as the importance of a robust underlying platform and architecture to enable an eClinical suite.
To access the webinar on demand visit: http://www.perceptive.com/News/Webinars/index.html.
# # #
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.